Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment
Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment
复制标题
DOI：
10.5858/arpa.2012-0295-sa
复制
发表时间：
2012-12-01
影响因子：
4.6
通讯作者：
Bunn, Paul A., Jr.
中科院分区：
文献类型：
--
作者：
Bunn, Paul A., Jr.
肺癌是世界范围内癌症死亡的主要原因。吸烟是肺癌的主要原因，戒烟是降低肺癌死亡率的既定方法。虽然前吸烟者的肺癌风险降低，但与从不吸烟者相比，他们的风险终身增加。新的化学预防策略，如口服或吸入前列环素类似物，对这些受试者有希望。在50岁以上的高危重度吸烟者中，低剂量螺旋CT筛查可使肺癌死亡率降低20%。然而，高假阳性率（96%）意味着筛选的患者需要在有经验的中心进行对照随访。越来越多的晚期肺癌患者的基因中存在分子驱动因子，口服酪氨酸激酶抑制剂已被开发出来。(Arch 2012; 136：1478-1481; doi：10.5858/arpa.2012-0295-SA）
Lung cancer is the leading worldwide cause of cancer deaths. Smoking is the dominant cause of lung cancer and smoking cessation is the established method to reduce lung cancer mortality. While lung cancer risk is reduced in former smokers, they have a lifelong increase in risk, compared to never-smokers. Novel chemoprevention strategies, such as oral or inhaled prostacyclin analogs, hold promise for these subjects. Low-dose spiral computed tomography screening reduced lung cancer mortality by 20% in high-risk heavy smokers older than 50 years. However, the high false-positive rate (96%) means that screened patients required controlled follow-up in experienced centers. An increasing percentage of patients with advanced lung cancer have molecular drivers in genes for which oral tyrosine kinase inhibitors have been developed. (Arch Pathol Lab Med. 2012; 136: 1478-1481; doi: 10.5858/arpa.2012-0295-SA)